In that case, a clinical translation of CDX2 and SOX2 as biomarkers of potentially targetable sub-sets of gastric cancers would be more straightforward, given that the infrastructure for IHC performance and evaluation exist widely in clinical pathology laboratories. The gene discussed is SOX2; the disease is gastric cancer.